WELCOME TO G-FINDER

The G-FINDER survey tracks global public, private, and philanthropic investment into product research and development (R&D) for neglected diseases. These are diseases that predominantly affect developing countries and for which products are needed but there is insufficient commercial pull to stimulate R&D.

The survey includes R&D of drugs, vaccines, diagnostics, insecticides, microbicides and other pharmaceutical tools, from basic research through to post-registration studies.

The project is conducted by Policy Cures Research and funded by the Bill & Melinda Gates Foundation. In addition, the 2017 survey will collect data on R&D investments for emerging infectious diseases (EIDs). For more information, please refer to the frequently asked questions.




G-FINDER Reports

Survey results are published and launched as yearly G-FINDER reports.

G-FINDER reports from previous years:

2017. Neglected Disease Research & Development: Reflecting on a decade of global investment

2016. Neglected Disease Research & Development: A pivotal moment for global health

2015. Neglected Disease Research & Development: The Ebola effect

2014. Neglected Disease Research & Development: Emerging trends

2013. Neglected Disease Research & Development: The public divide

2012. Neglected Disease Research & Development: A five year review

2011. Neglected Disease Research & Development: Is innovation under threat?

2010. Neglected Disease Research & Development: Is the global financial crisis changing R&D

2009. Neglected Disease Research & Development: New times, new trends

2008. Neglected Disease Research & Development: How much are we really spending?


G-FINDER Public Search Tool

The underlying data behind the G-FINDER reports is also made freely available via the G-FINDER public search tool (with confidential industry data aggregated and anonymised).


Key dates


21 July 2017
Deadline for completing the survey

SURVEY CLOSED

December 2017 
Publication and global launch of the tenth annual report


0 days left to complete the survey.

SURVEY CLOSED

Your login has expired